Journal
FRONTIERS IN PHARMACOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.816588
Keywords
type 2 diabetes; heart failure; insulin signaling pathway; myocardial energy metabolism; insulin resistance; drugs
Categories
Funding
- National Natural Science Foundation of China [81973493]
- Science and Technology Research Special Project of Sichuan Administration of Traditional Chinese Medicine [2021MS016]
- Open Fund Project of State Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Chinese Medicine [GZSYS202005]
Ask authors/readers for more resources
Type 2 diabetes mellitus (T2DM) and heart failure (HF) are diseases with high morbidity and mortality. Their combination is common in middle-aged and elderly individuals, making treatment challenging. Abnormal insulin signaling pathway, a common pathogenic mechanism, could serve as a specific target for the treatment of T2DM patients with HF.
Type 2 diabetes mellitus (T2DM) and heart failure (HF) are diseases characterized by high morbidity and mortality. They often occur simultaneously and increase the risk of each other. T2DM complicated with HF, as one of the most dangerous disease combinations in modern medicine, is more common in middle-aged and elderly people, making the treatment more difficult. At present, the combination of blood glucose control and anti-heart failure is a common therapy for patients with T2DM complicated with HF, but their effect is not ideal, and many hypoglycemic drugs have the risk of heart failure. Abnormal insulin signaling pathway, as a common pathogenic mechanism in T2DM and HF, could lead to pathological features such as insulin resistance (IR), myocardial energy metabolism disorders, and vascular endothelial disorders. The therapy based on the insulin signaling pathway may become a specific therapeutic target for T2DM patients with HF. Here, we reviewed the mechanisms and potential drugs of insulin signaling pathway in the treatment of T2DM complicated with HF, with a view to opening up a new perspective for the treatment of T2DM patients with HF and the research and development of new drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available